CIMIT Gives Academic Community Voice In Least Burdensome Debate
This article was originally published in The Gray Sheet
The Center for Innovative Minimally Invasive Therapy (CIMIT) is planning a public forum that will convene representatives from FDA, industry and the academic community to discuss the "least burdensome" process for device evaluation in several specific product areas.
You may also be interested in...
Reviewers of 510(k) premarket submissions should limit their analyses to claims "that present a major impact on the intended use of the device," according to principles set forth in a least burdensome industry task force (LBITF) and FDA draft document released for comment on FDA's website March 20.
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.